BCR–ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells-Reference-Cited by-同舟云学术

BCR–ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells

Published:2016-05-15 Issue:1 Volume:15 Page:15-26
ISSN:1672-7681
Container-title:Cellular & Molecular Immunology
language:en
Short-container-title:Cell Mol Immunol

Author:

Ueda Norihiro,Zhang Rong,Tatsumi Minako,Liu Tian-Yi,Kitayama Shuichi,Yasui Yutaka,Sugai Shiori,Iwama Tatsuaki,Senju Satoru,Okada Seiji,Nakatsura Tetsuya,Kuzushima Kiyotaka,Kiyoi Hitoshi,Naoe Tomoki,Kaneko Shin,Uemura Yasushi

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Link

http://www.nature.com/articles/cmi20167.pdf

Reference44 articles.

1. Deininger MW, Goldman JM, Melo JV . The molecular biology of chronic myeloid leukemia. Blood 2000; 96: 3343–3356.

2. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.

3. Burchert A, Saussele S, Eigendorff E, Muller MC, Sohlbach K, Inselmann S et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia 2015; 29: 1331–1335.

4. Hehlmann R, Saussele S . Treatment of chronic myeloid leukemia in blast crisis. Haematologica 2008; 93: 1765–1769.

5. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013; 121: 4439–4442.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aerobic glycolysis enables the effector differentiation potential of stem-like CD4+ T cells to combat cancer;Cellular & Molecular Immunology;2024-03-21

2. Tumor immunology;Clinical Immunology;2023

3. Antigen Targets for the Development of Immunotherapies in Leukemia;International Journal of Molecular Sciences;2019-03-20

4. Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer;Cancer Immunology, Immunotherapy;2018-10-10

5. Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response;Stem Cell Reports;2018-06